Cancer Cured?!
- Started
- Last post
- 31 Responses
- sofakingbanned0
oh its coming, you better believe its coming. :}
- HA!!!! I saw this thread and thought: Zombies. Cure Cancer, get zombies...
Looks like I had the same idea 5 years ago :Dsofakingback
- HA!!!! I saw this thread and thought: Zombies. Cure Cancer, get zombies...
- monkeyshine0
sounds a bit faustian
- OP310
isnt this how the movie "I Am Legend" started?
- monkeyshine0
maybe we can use this drug to kick HIV's ass after it kicks cancers ass: http://healthland.time.com/2011/…
- Ianbolton0
^ So when you say supportive, you mean watch them go through heartbreaking chemotherapy? My friend is convinced if her child gets cancer she'll refuse chemo and treat him with homeopathy/alternative treatments. A lot of people seem to be under the apprehension that their medical knowledge of eating coconut oil boiled up in cannabis can totally destroy and possibly cure the disease. How do I go about supporting somebody who wishes to push their medical advice on everyone they know? With zero medical qualifications or background - just an internet connection?
- you're talking to spamkingsteven
- Oh yeah. I'm also hungover to fuckIanbolton
- Chemo is only 2.1% effective toward 5 year survival and utterly destroys the body.set
- I know three people, one of them a 2 year old girl, who took chemo and died anyway, and it makes their lives a living hell one their still around.set
- while they're still around*
I wouldn't recommend it to anyone, personally.set - Thanks, I don't feel like I'm speaking to spam now. But the options are also limited and it's what we've been using for years. Yeah?Ianbolton
- Nor I, unless they had cancer and it offered a distinct chance of their surviving.
http://scienceblogs.…detritus - lol there's the I believe everything the media tells me guy againset
- sorry that was complete trolling bate, I just can't help myself when I see that detritus handle.set
- bait, even. Though bate could work too,set
- ORAZAL-1
Total PSA
WARNING: The concentration of total PSA in a given specimen, determined with assays from different manufacturers, can vary due to differences in assay methods and reagent specificity. The results reported by the laboratory to the physician must include the identity of the total PSA assay used. Values obtained with different assay methods, including Abbott PSA assays, cannot be used interchangeably. If, in the course of monitoring a patient, the assay method used for determining total PSA levels serially is changed, additional sequential testing should be carried out. Prior to changing assays, the laboratory MUST confirm baseline values for patients being serially monitored.
NAME
ARCHITECT Total PSA (Prostate Specific Antigen)
INTENDED USE
The ARCHITECT Total PSA assay is a Chemiluminescent Microparticle Immunoassay (CMIA) for the quantitative determination of total PSA (both free PSA and PSA complexed to alpha-1-antichymotrypsin) in human serum:
1. As an aid in the detection of prostate cancer when used in conjunction with digital rectal exam (DRE) in men 50 years or older. Prostatic biopsy is required for diagnosis of cancer.
2. As an adjunctive test to aid in the management of prostate cancer patients.
SUMMARY AND EXPLANATION OF TEST
Prostate specific antigen (PSA), a member of the human kallikrein gene family, is a serine protease with chymotrypsin-like activity. The mature form of PSA is a single chain glycoprotein of 237 amino acids containing 7-8% carbohydrate as a single N-linked oligosaccharide side chain. PSA has a molecular weight of approximately 30,000 daltons.1,8,33,34
The major site of PSA production is the glandular epithelium of the prostate. PSA has also been found in breast cancers, salivary gland neoplasms, periurethral and anal glands, cells of the male urethra, breast milk, blood and urine.1,2 PSA produced in the prostate is secreted into the seminal fluid in high concentrations. A major function of PSA is the proteolytic cleavage of gel-forming proteins in the seminal fluid, resulting in the liquification of the seminal gel and increased sperm mobility.1 Low levels of PSA are found in the blood as a result of leakage of PSA from the prostate gland. Increasing levels of serum PSA are associated with prostatic pathology, including prostatitis, benign prostatic hyperplasia (BPH), and cancer of the prostate.1,3-7
PSA occurs in three major forms in blood. The major immunodetectable form is PSA complexed with the serine protease inhibitor, alpha- 1-antichymotrypsin (PSA-ACT). Uncomplexed, or free PSA, is the other immunodetectable form of PSA in serum. The majority of free PSA in serum appears to be an inactive form that cannot complex with protease inhibitors and may be either a PSA zymogen or an enzymatically-inactive, cleaved form of PSA. Equimolar-response PSA assays have an equivalent response to both free PSA and PSA-ACT.1 The ARCHITECT Total PSA assay is an equimolar assay. A third form of PSA, a complex with alpha-2-macroglobulin, is not detectable with current immunoassays for PSA due to the engulfment and subsequent masking of PSA epitopes by the alpha-2-macroglobulin molecule.1,8,9 Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer deaths in men in the United States.10 Early diagnosis of carcinoma of the prostate is hindered by the lack of symptoms in men with localized tumors. Therefore, early detection requires a simple, safe, and inexpensive test for the disease in asymptomatic men. The traditional method for detection of prostate cancer is the digital rectal examination (DRE). However, only 30 to 40% of cancers detected by DRE screening are expected to be confined to the prostate. The frequent finding of locally advanced prostate cancer in screened patients may be due to the inability of DRE to detect tumors of small volume that are most likely to be confined to the prostate.11 Since patients with small tumors are believed to have the best prognosis, it can be concluded that DRE has limited sensitivity in detecting those tumors with the greatest potential for cure.12
In a 1990 publication by Cooner et al., data was presented regarding the clinical use of other diagnostic modalities such as prostate ultrasonography and serum prostate specific antigen for early detection of prostate cancer. This study found that there was a significant increase in predictability for cancer when the DRE and PSA tests were abnormal.13 Several other studies have shown that the
measurement of serum PSA concentrations offers several advantages in the early detection of prostate cancer. The procedure is more acceptable to patients, the result is objective and quantitative, and is independent of the examiners skill. In several recent studies of healthy men 50 years or older, serum PSA levels had the greatest ability to predict prostate cancer. These studies concluded that not only is serum PSA measurement a useful addition to rectal examination and ultrasonography in the detection of prostate cancer, but that it is also the most accurate of the three tests for this purpose.14,15 In January 1992, the American Urological Association endorsed annual examination with DRE and PSA, for early detection of prostate cancer, beginning at age 50.16 This was reaffirmed by the American Cancer Society in November 1992.17 The combined use of DRE and PSA has been shown to result in an increased detection of early stage prostate cancer; however, the benefit of early detection on patient outcome has not been proven and is the subject of ongoing clinical trials.4-7,13-15,18,19
PSA testing can have significant value in detecting metastatic or persistent disease in patients following surgical or medical treatment of prostate cancer. Persistent elevation of PSA following treatment, or an increase in a post-treatment PSA level is indicative of recurrent or residual disease. PSA testing is widely accepted as an adjunctive test in the management of prostate cancer patients.3-7
BIOLOGICAL PRINCIPLES OF THE PROCEDURE
The ARCHITECT Total PSA assay is a two-step immunoassay to determine the presence of total PSA (both free PSA and PSA complexed to alpha-1-antichymotrypsin) in human serum, using Chemiluminescent Microparticle Immunoassay (CMIA) technology with flexible assay protocols, referred to as Chemiflex.
In the first step, sample and anti-PSA coated paramagnetic microparticles are combined. PSA present in the sample binds to the anti-PSA coated microparticles. After washing, anti-PSA acridinium- labeled conjugate is added in the second step. Pre-Trigger and Trigger Solutions are then added to the reaction mixture; the resulting chemiluminescent reaction is measured as relative light units (RLUs). A direct relationship exists between the amount of total PSA in the sample and the RLUs detected by the ARCHITECT i* optical system.
For additional information on system and assay technology, refer to the ARCHITECT System Operations Manual, Section 3.
* i = immunoassay
REAGENTS
Reagent Kit, 100 Tests/500 Tests
NOTE: Reagent Kit Configurations vary based on order.
ARCHITECT Total PSA Reagent Kit (7K70)
1 or 4 Bottle(s) (6.6 mL for 100 test bottle/
27.0 mL for 500 test bottle) Anti-PSA (mouse, monoclonal) coated Microparticles in TRIS buffer with protein (bovine) stabilizers. Preservative: Antimicrobial Agents.
1 or 4 Bottle(s) (5.9 mL for 100 test bottle/26.3 mL for 500 test bottle) Anti-PSA (mouse, monoclonal) acridinium-labeled Conjugate in MES buffer with protein (bovine) stabilizers. Minimum concentration: 10 ng/mL. Preservative: Antimicrobial Agents.
Assay Diluent
ARCHITECT i Multi-Assay Manual Diluent (7D82-50)
1 Bottle (100 mL) ARCHITECT i
Multi-Assay Manual Diluent containing phosphate buffered saline solution. Preservative: Antimicrobial Agent.
Other Reagents
ARCHITECT i Pre-Trigger Solution
Pre-Trigger Solution containing 1.32% (w/v) hydrogen peroxide.
ARCHITECT i Trigger Solution
Trigger Solution containing 0.35N sodium hydroxide.
ARCHITECT i Wash Buffer
NOTE: Bottle and volume varies based on order.
Wash Buffer containing phosphate buffered saline solution. Preservative: Antimicrobial Agent.- For those doubting the pertinence of LilianaSnowden's post.
http://www.qbn.com/r…ORAZAL - too short. didn't read.sarahfailin
- i prefer long-form journalism thank yousarahfailin
- For those doubting the pertinence of LilianaSnowden's post.
